Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2020 07:05 ET | Source: Myriad Genetics, Inc.

New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy

SALT LAKE CITY, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it is presenting new data at the...
February 12, 2020 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference

SALT LAKE CITY, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that R. Bryan Riggsbee, president and...
February 11, 2020 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer

SALT LAKE CITY, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary...
February 06, 2020 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Announces Leadership Transition

R. Bryan Riggsbee, Chief Financial Officer Appointed Interim President and CEO Mark C. Capone Resigns, Effective Immediately SALT LAKE CITY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc....
February 06, 2020 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results

Total Second-Quarter Revenues of $195.1 MillionSecond-Quarter Diluted EPS of ($0.11) and Adjusted EPS of $0.23 SALT LAKE CITY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN,...
January 30, 2020 07:05 ET | Source: Myriad Genetics, Inc.

Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020

SALT LAKE CITY, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal...
January 22, 2020 18:36 ET | Source: Myriad Genetics, Inc.

Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer

SALT LAKE CITY, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary...
January 21, 2020 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer

SALT LAKE CITY, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a...
January 14, 2020 07:05 ET | Source: Myriad Genetics, Inc.

Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology

SALT LAKE CITY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Thomas P. Slavin, M.D.,...
January 06, 2020 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at the J.P. Morgan 2020 Healthcare Conference

SALT LAKE CITY, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that Mark C. Capone, president and CEO,...